Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Rotmensz

Showing results (41-50 of 100) with videos related to

Pageof 10
Sort By:
European Journal of Cancer & Clinical Oncology|August 1, 1988
Esorubicin in advanced ovarian epithelial cancer. A phase II study of the EORTC Gynecological Cancer Cooperative GroupA T van Oosterom, M S Aapro, F Carnino, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinomaC H Veenhof, M E van der Burg, M Nooy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 11, 2012
Risk factors associated with recurrence after nipple-sparing mastectomy for invasive and intraepithelial neoplasiaJ Y Petit, U Veronesi, R Orecchia, et al.
Ecancermedicalscience|January 26, 2012
Long-term outcomes of a pilot CT screening for lung cancerG Veronesi, P Maisonneuve, L Spaggiari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2012
Outcome and clinical-biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastasesE Munzone, E Botteri, A Esposito, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 4, 2011
Impact on survival of the number of lymph nodes removed in patients with node-negative gastric cancer submitted to extended lymph node dissectionR Biffi, E Botteri, S Cenciarelli, et al.
Breast Cancer Research and Treatment|April 21, 2015
Angiosarcoma and atypical vascular lesions of the breast: diagnostic and prognostic role of MYC gene amplification and protein expressionC Fraga-Guedes, S André, M G Mastropasqua, et al.
European Journal of Cancer & Clinical Oncology|April 1, 1989
Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy. An EORTC Breast Cancer Co-operative Group Trial (10792)R D Rubens, H Bartelink, E Engelsman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2007
Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implicationsF Nolé, E Munzone, L Zorzino, et al.
European Journal of Gynaecological Oncology|January 1, 1990
Randomized comparison of cyclophosphamide, doxorubicin and cisplatin (CAP) versus cyclophosphamide and doxorubicin (CA) for the treatment of advanced ovarian cancer (ADOVCA). A EORTC Gynecological Cancer Cooperative Group StudyC F de Oliveira, A J Lacave, C Villani, et al.
Pageof 10

Showing results (41-50 of 100) with videos related to

Sort By:
Pageof 10
European Journal of Cancer & Clinical Oncology|August 1, 1988
Esorubicin in advanced ovarian epithelial cancer. A phase II study of the EORTC Gynecological Cancer Cooperative GroupA T van Oosterom, M S Aapro, F Carnino, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinomaC H Veenhof, M E van der Burg, M Nooy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 11, 2012
Risk factors associated with recurrence after nipple-sparing mastectomy for invasive and intraepithelial neoplasiaJ Y Petit, U Veronesi, R Orecchia, et al.
Ecancermedicalscience|January 26, 2012
Long-term outcomes of a pilot CT screening for lung cancerG Veronesi, P Maisonneuve, L Spaggiari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2012
Outcome and clinical-biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastasesE Munzone, E Botteri, A Esposito, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 4, 2011
Impact on survival of the number of lymph nodes removed in patients with node-negative gastric cancer submitted to extended lymph node dissectionR Biffi, E Botteri, S Cenciarelli, et al.
Breast Cancer Research and Treatment|April 21, 2015
Angiosarcoma and atypical vascular lesions of the breast: diagnostic and prognostic role of MYC gene amplification and protein expressionC Fraga-Guedes, S André, M G Mastropasqua, et al.
European Journal of Cancer & Clinical Oncology|April 1, 1989
Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy. An EORTC Breast Cancer Co-operative Group Trial (10792)R D Rubens, H Bartelink, E Engelsman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2007
Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implicationsF Nolé, E Munzone, L Zorzino, et al.
European Journal of Gynaecological Oncology|January 1, 1990
Randomized comparison of cyclophosphamide, doxorubicin and cisplatin (CAP) versus cyclophosphamide and doxorubicin (CA) for the treatment of advanced ovarian cancer (ADOVCA). A EORTC Gynecological Cancer Cooperative Group StudyC F de Oliveira, A J Lacave, C Villani, et al.
Pageof 10